Comparing Lisata Therapeutics (LSTA) and The Competition

Lisata Therapeutics (NASDAQ:LSTA) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Lisata Therapeutics to similar companies based on the strength of its valuation, profitability, institutional ownership, risk, dividends, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent recommendations for Lisata Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	2	0	0	1.67
Lisata Therapeutics Competitors	9789	15054	45300	1571	2.54

As a group, “Biotechnology” companies have a potential upside of 97.60%. Given Lisata Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics has less favorable growth aspects than its rivals.

Risk & Volatility

Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Lisata Therapeutics’ rivals have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Insider and Institutional Ownership

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 8.4% of Lisata Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Lisata Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Lisata Therapeutics Competitors	-9,046.59%	-199.78%	-30.61%

Valuation & Earnings

This table compares Lisata Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lisata Therapeutics	$170,000.00	-$16.59 million	-0.66
Lisata Therapeutics Competitors	$691.13 million	$10.43 million	-10.02

Lisata Therapeutics’ rivals have higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Lisata Therapeutics rivals beat Lisata Therapeutics on 10 of the 12 factors compared.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.